MedPath

Impact on the Time to Diagnosis of Serious Postoperative Complications by a Controlled Connected Medical Device

Not Applicable
Conditions
Medical Device
Interventions
Device: Active "SMART ANGEL" solution
Device: Inactive "SMART ANGEL" solution
Registration Number
NCT05380310
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Brief Summary

Post-operative mortality in case of scheduled surgery is 3% in France (Lancet 2013) mainly due to cardiovascular or respiratory complications, by decompensation of pre-existing pathologies.

Complications due to the medical practice are the third cause of morbidity (BMJ, 2016). More than half are preventable and are mainly observed in surgical patients. In conventional hospitalization, excluding intensive care, monitoring is done discontinuously for most of the patients, which does not allow early diagnosis of a vital cardiovascular or respiratory failure.

Diagnosis and late treatment do not allow good recovery. The early identification of a vital failure by the continuous monitoring of three simple physiological parameters (SpO2, heart rate and respiratory rate) would allow faster management by the hospital staff and a reduction in immediate and possibly delayed postoperative mortality.

Detailed Description

The challenge of this research is to transpose in an ordinary hospitalization unit the continuous monitoring of vital functions carried out in intensive care by the continuous measurement of simple parameters using the "SMART ANGEL Intra-hospital" System's (connected medical devices and alerts).

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
2000
Inclusion Criteria
  • Age ≥ 18 years
  • Patients receiving a scheduled non-ambulatory surgical or interventional procedure
  • Affiliation to a social security scheme, beneficiary or entitled person (excluding AME)
  • Patient's written consent or of the trusted person in case of physical incapacity
Exclusion Criteria
  • Inclusion in emergency situations
  • ASA1 patient (without associated pathology)
  • Patient with a multi-drug resistant germ in isolation
  • Known linguistic inability of the patient to understand the study
  • Known pregnancy or breastfeeding woman
  • Patients with implantable pacemakers, implantable defibrillators or neurostimulators.
  • Person under legal protection or unable to give consent
  • Person deprived of liberty by judicial or administrative decision

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Active alertsActive "SMART ANGEL" solution"SMART ANGEL Intra-hospital" System with active alerts
Inactive alertsInactive "SMART ANGEL" solution"SMART ANGEL Intra-hospital" System with inactive alerts
Primary Outcome Measures
NameTimeMethod
Difference in response times for nursesbetween inclusion visit and day 30

Difference in response times between the two groups as measured by the difference between the exact time of occurrence of the complication and the time of caregiver intervention.

Secondary Outcome Measures
NameTimeMethod
Length of staybetween inclusion visit and day 30
Mortality during hospitalisationbetween inclusion visit and day 30

Within 30 days of the intervention

Rate of calls to the doctor on dutybetween inclusion visit and day 30
Percentage of re-hospitalization within 30 daysbetween inclusion visit and day 30
Percentage of hospitalisations in follow-up care and rehabilitation care unitsbetween inclusion visit and day 30
Patient acceptabilitybetween inclusion visit and day 30

Quantitative and qualitative assessment of the device's usability by the patient via Questionnaire and interview

Mortality within 30 days of surgerybetween inclusion visit and day 30
Percentage of transfers to intensive care unitbetween inclusion visit and day 30
ICU length of staybetween inclusion visit and day 30
Percentage of patients managed at homebetween inclusion visit and day 30
False positive ratebetween inclusion visit and day 30

Alert without complication for the patient

Acceptability of care teamsbetween inclusion visit and day 30

Questionnaire and interview

Incremental cost-effectiveness ratiobetween inclusion visit and day 30

Trial Locations

Locations (1)

Assistance Publique Hôpitaux de Paris - CHU Henri Mondor

🇫🇷

Créteil, France

© Copyright 2025. All Rights Reserved by MedPath